

CONFLICTS OF INTEREST

This forum dedicated to the guidelines from the FDA about “Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization” presents views from various actors and agents with and without direct industry ties. We present here the collected Disclosures of Conflicts of Interest in advance of the forum so that readers are aware of the various positions being presented herein.

CONFLICTS OF INTEREST

Mitch Zeller, JD, is the director of the US Food and Drug Administration, Center for Tobacco Products. He has no conflicts of interest to declare.

Brian A. King, PhD, MPH, is with the Office on Smoking and Health, Centers for Disease Control and Prevention. He has no conflicts of interest to declare.

Kurt M. Ribisl, PhD, is with the Lineberger Comprehensive Cancer Center and the Gillings School of Global Public Health, University of North Carolina, Chapel Hill. He has served as an expert consultant in litigation against cigarette and e-cigarette manufacturers. Natalie Hemmerich, JD, MPH, is with the Public Health Law Center, St Paul, MN. Seth M. Noar, PhD, is with the Lineberger Comprehensive Cancer Center, and the Hussman School of Journalism and Media, University of North Carolina, Chapel Hill. Neither Natalie Hemmerich nor Seth Noar has any conflicts to disclose.

Micah L. Berman, JD, is with the College of Public Health and Moritz College of Law, Ohio State University, Columbus. Desmond Jenson, JD, is with the Public Health Law Center, Mitchell Hamline College of Law, St. Paul, MN. Neither author has any conflicts of interest to disclose.

Rebekah E. Gee, MD, MPH, is with Louisiana State University Health Care Services, New Orleans. She reports no relationships or financial interest with any entity that would pose a conflict of interest with the subject matter of this article.

Brian E. Erkkila, PhD, and Derek Yach, MPH, are with of the Foundation for a Smoke-Free World, New York, NY. The Foundation for a Smoke-Free World has received contributions from Philip Morris International (PMI) in 2018 and 2019, each in the amount of US \$80 million. PMI has pledged to contribute \$80 million annually for the next 10 years. Under the Foundation’s bylaws and pledge agreement, PMI and the tobacco industry generally are precluded from having any control of or influence over how the foundation spends its funds or focuses its activities. Patricia I. Kovacevic, JD, is with RegulationStrategies, Tampa, FL. She has no conflicts of interest to disclose.

Brad Rodu’s, DDS, is with the Department of Medicine and James Graham Brown Cancer Center, University of Louisville, Louisville, KY. His research is supported by unrestricted grants from tobacco manufacturers to the University of Louisville and by the Kentucky Research Challenge Trust Fund.

Ethan Nadelmann, JD, PhD, is the founder and former executive director (2000–2017) of the Drug Policy Alliance, New York, NY. He has no conflicts of interest to disclose.

Adam R. Houston is a PhD candidate in the Faculty of Law, University of Ottawa, ON, Canada. Amelia Howard is a PhD candidate in the Department of Sociology and Legal Studies, University of Waterloo, ON, Canada. David Sweanor, JD, is with the Centre for Health Law, Policy and Ethics, University of Ottawa. A. Howard has provided consultation services to Keller and Heckman, LLP, a law firm representing independent e-cigarette and e-liquid manufacturers, suppliers, and trade associations in matters of US Food and Drug Administration’s regulatory and corporate compliance. A. R. Houston and D. Sweanor declare no conflict of interest, financial or otherwise.

Martin McKee, MD, is with the London School of Hygiene & Tropical Medicine, London, England. He has no conflicts of interest to disclose.

Alex Wodak, MBBS, is an emeritus consultant at St Vincent’s Hospital, Sydney, Australia. Colin P. Mendelsohn, MBBS, is with the School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia. Neither author has any conflicts of interest to disclose.

Alex Liber, MSPH, Zachary Cahn, PhD, Aidan Larsen, BA, and Jeffrey Drope, PhD, are with the Economic and Health Policy Research, Intramural Research, American Cancer Society. Alex Liber is also with the Department of Health Management and Policy, School of Public Health, University of Michigan, Ann Arbor. Aidan Larsen is also with the Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, GA. The authors have no conflicts of interest to disclose.

Thomas J. Miller, JD, is the Attorney General of Iowa, Office of the Attorney General, State of Iowa. He has no conflicts of interest to disclose. [AJPH](#)

doi: 10.2105/AJPH.2020.110.6.771